DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
DJI46,558.47-0.26%
GDAXI23,447.29-0.60%
GSPC6,632.19-0.61%
HSI25,465.60-0.98%
IXIC22,105.36-0.93%
N22553,819.61-1.16%
AAPL250.12-2.21%
AMZN207.67-0.89%
CL98.71+3.11%
EURUSD1.1423-0.82%
GBPUSD1.3223-0.93%
GC5,061.70-1.25%
GOOG301.46-0.58%
JPM283.44+0.19%
META613.71-3.83%
MSFT395.55-1.58%
NVDA180.25-1.59%
TSLA391.20-0.96%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
DEU FAZ Finanzen DE

Pharmafirma in Investorenhand: Neuraxpharm spricht von Börsengang im Jahr 2027

Der Investor Permira lotete einen Verkauf der milliardenschweren Pharmafirma aus. Jetzt steuert er in Richtung Parkett – in Frankfurt und im kommenden Jahr.

Mar 10, 2026 &03411010202631; 16:41 UTC www.faz.net
Read original on www.faz.net ↗
↗
Positive for markets
Sentiment score: +65/100
Moderate impact Medium-term (weeks)
WHAT THIS MEANS
Neuraxpharm, a billion-euro pharmaceutical company owned by investor Permira, is planning an IPO in 2027, likely on the Frankfurt Stock Exchange. This strategic move signals confidence in the company's growth trajectory and represents a significant capital market event for the German pharma sector.
AI CONFIDENCE
75% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↑
FTSE MIB (Italy)
FTSEMIB.MIIndex
Expected to rise
Positive sentiment for European pharma sector and Frankfurt exchange activity
↑
Euro Stoxx 50
^STOXX50EIndex
Expected to rise
European healthcare and pharma sector strength from major IPO pipeline
↑
EU→.PA
EU→.PAStock
Expected to rise
Potential competitive and sector-wide positive sentiment for European pharma companies
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Monitor Neuraxpharm's development and competitive positioning through 2027. Consider accumulating positions in European pharma indices and related healthcare stocks as the IPO timeline approaches, as successful mega-cap pharma listings typically boost sector sentiment.
KEY SIGNALS
Major IPO planned for 2027Frankfurt Stock Exchange listing targetBillion-euro valuation companyPermira exit strategy confirmationEuropean pharma sector strength
SECTORS INVOLVED
PharmaceuticalsHealthcareCapital Markets
Analysis generated on Mar 11, 2026 at 01:21 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by FAZ Finanzen. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

FTSE 100 Live: Stocks to dip as oil surges back to $100 after tankers attacked
City AM Mar 12, 06:30 Negative
Elfin Agro India share price makes flat listing, shares list at ₹47.30 on BSE SME, a premium of 0.63% from issue price
Livemint Mar 12, 06:17 Neutral
Middle East conflicts could trigger EU inflation above 3% - report
Seeking Alpha Mar 12, 06:11 Negative
Standard Bank Profit Rises to Record on Fee Growth, Client Gains
Bloomberg Markets Mar 12, 06:08 Positive
Starkare resultat än väntat för Rusta
Dagens Industri Mar 12, 06:05 Positive